{"context":{"query":">>mesh>>pharmgkb_clinical","source_dataset":"mesh","target_dataset":"pharmgkb_clinical"},"stats":{"queried":1,"total":42,"mapped":1},"pagination":{"has_next":false},"schema":"id|variant|gene|type|level_of_evidence|chemicals|phenotypes","mappings":[{"input":"D011565","source":"D011565|Psoriasis","targets":["HLA-C*06:02_HLA-C_1|HLA-C*06:02|HLA-C|Efficacy|3|ustekinumab|Psoriasis","HLA-C*06:02_HLA-C_2|HLA-C*06:02|HLA-C|Efficacy|3|methotrexate|Psoriasis","RS10782001_FBXL19_1|rs10782001|FBXL19|Toxicity|3|Tumor necrosis factor alpha (TNF-alpha) inhibitors|Psoriasis","RS11126740_CTNNA2_1|rs11126740|CTNNA2|Efficacy|3|Tumor necrosis factor alpha (TNF-alpha) inhibitors|Psoriasis","RS11209026_IL23R_1|rs11209026|IL23R|Toxicity|3|Tumor necrosis factor alpha (TNF-alpha) inhibitors|Psoriasis","RS11280056_TYMS_4|rs11280056|TYMS|Toxicity|4|methotrexate|Drug Toxicity;Hematopoietic stem cell transplantation;Psoriasis;Rheumatoid arthritis;Toxic liver disease","RS1143623_IL1B_2|rs1143623|IL1B|Efficacy|3|Tumor necrosis factor alpha (TNF-alpha) inhibitors;ustekinumab|Psoriasis","RS1143627_IL1B_2|rs1143627|IL1B|Efficacy|3|Tumor necrosis factor alpha (TNF-alpha) inhibitors;ustekinumab|Psoriasis","RS11465996_LY96_1|rs11465996|LY96|Efficacy|3|Tumor necrosis factor alpha (TNF-alpha) inhibitors|Psoriasis","RS11938228_TLR2_1|rs11938228|TLR2|Efficacy|3|Tumor necrosis factor alpha (TNF-alpha) inhibitors|Inflammatory Bowel Diseases;Psoriasis","RS12191877_HLA-C_1|rs12191877|HLA-C|Efficacy|3|Tumor necrosis factor alpha (TNF-alpha) inhibitors|Psoriasis","RS12885713_CALM1_1|rs12885713|CALM1|Efficacy|3|cyclosporine|Psoriasis","RS13120400_ABCG2_1|rs13120400|ABCG2|Efficacy|3|methotrexate|Psoriasis","RS1695_GSTP1_2|rs1695|GSTP1|Efficacy|3|dimethyl fumarate|Psoriasis","RS17731538_ABCG2_1|rs17731538|ABCG2|Efficacy|3|methotrexate|Psoriasis","RS1799724_TNF_1|rs1799724|TNF|Efficacy|4|Tumor necrosis factor alpha (TNF-alpha) inhibitors|Crohn Disease;Psoriasis;Rheumatoid arthritis;Spondylitis;Ankylosing","RS1800629_TNF_1|rs1800629|TNF|Efficacy|2B|etanercept|Arthritis;Psoriatic;Crohn Disease;Inflammation;Psoriasis;Rheumatoid arthritis;Spondylitis;Ankylosing","RS1800795_IL6_4|rs1800795|IL6|Efficacy|3|Tumor necrosis factor alpha (TNF-alpha) inhibitors|Psoriasis","RS1801274_FCGR2A_5|rs1801274|FCGR2A|Efficacy|4|adalimumab;etanercept;infliximab|Psoriasis","RS2238476_ABCC1_1|rs2238476|ABCC1|Efficacy,Toxicity|3|methotrexate|Psoriasis","RS246240_ABCC1_1|rs246240|ABCC1|Toxicity|3|methotrexate|Drug Toxicity;Psoriasis","RS2546890_IL12B_1|rs2546890|IL12B|Efficacy|3|Tumor necrosis factor alpha (TNF-alpha) inhibitors|Psoriasis","RS28364006_ABCC1_1|rs28364006|ABCC1|Efficacy|3|methotrexate|Psoriasis","RS2916205_PGLYRP4_1|rs2916205|PGLYRP4|Efficacy|3|Tumor necrosis factor alpha (TNF-alpha) inhibitors|Psoriasis","RS3087243_CTLA4_1|rs3087243|CTLA4|Toxicity|3|Tumor necrosis factor alpha (TNF-alpha) inhibitors|Psoriasis","RS3213094_IL12B_1|rs3213094|IL12B|Efficacy|3|ustekinumab|Psoriasis","RS352139_TLR9_2|rs352139|TLR9|Efficacy|3|Tumor necrosis factor alpha (TNF-alpha) inhibitors|Psoriasis","RS35592_ABCC1_1|rs35592|ABCC1|Efficacy|3|methotrexate|Psoriasis;Rheumatoid arthritis","RS3761548_FOXP3_2|rs3761548|FOXP3|Efficacy|3|methotrexate|Psoriasis","RS396991_FCGR3A_4|rs396991|FCGR3A|Efficacy|3|adalimumab;etanercept;infliximab|Psoriasis","RS4696480_TLR2_2|rs4696480|TLR2|Efficacy|3|Tumor necrosis factor alpha (TNF-alpha) inhibitors|Psoriasis","RS4819554_IL17RA_1|rs4819554|IL17RA|Efficacy|3|Tumor necrosis factor alpha (TNF-alpha) inhibitors|Psoriasis","RS5744174_TLR5_1|rs5744174|TLR5|Efficacy|3|ustekinumab|Psoriasis","RS610604_TNFAIP3_1|rs610604|TNFAIP3|Efficacy|3|Tumor necrosis factor alpha (TNF-alpha) inhibitors|Arthritis;Psoriatic;Psoriasis","RS610604_TNFAIP3_2|rs610604|TNFAIP3|Efficacy|4|ustekinumab|Psoriasis","RS6427528_CD84_1|rs6427528|CD84|Efficacy|3|etanercept|Psoriasis;Rheumatoid arthritis","RS651630_SLC12A8_1|rs651630|SLC12A8|Toxicity|3|Tumor necrosis factor alpha (TNF-alpha) inhibitors|Psoriasis","RS6908425_CDKAL1_1|rs6908425|CDKAL1|Efficacy|3|Tumor necrosis factor alpha (TNF-alpha) inhibitors|Psoriasis","RS6920220_SH3BP2_TNFAIP3_1|rs6920220|SH3BP2,TNFAIP3|Efficacy|3|Tumor necrosis factor alpha (TNF-alpha) inhibitors|Arthritis;Psoriatic;Psoriasis","RS8177374_TIRAP_1|rs8177374|TIRAP|Efficacy|3|ustekinumab|Psoriasis","RS9304742_ZNF816_1|rs9304742|ZNF816|Efficacy|3|Tumor necrosis factor alpha (TNF-alpha) inhibitors|Psoriasis","RS96844_MAP3K1_1|rs96844|MAP3K1|Efficacy|3|Tumor necrosis factor alpha (TNF-alpha) inhibitors|Psoriasis"]}]}